Radioimmunoscintigraphy by Means of Melanoma Antibody

  • S. M. Larson
  • J. A. Carrasquillo
  • J. C. Reynolds
  • I. Hellström
  • K.-E. Hellström
Conference paper

Abstract

Disseminated malignant melanoma is incurable with presently available therapeutic regimens. Average survival of patients with this disease ranges from a few months to 1 year. Frequently, the disease is disseminated before surgical therapy removes the primary lesion and this dissemination is frequently unsuspected [1]. Significant improvements are needed in both the therapeutic and diagnostic aspects of management of patients with disseminated melanoma.

Keywords

Metastatic Melanoma Human Melanoma Popliteal Fossa Chondroitin Sulfate Proteoglycan Immune Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mastrangelo MJ, Rosenberg SA, Baker AR et al. (1982) Cutaneous melanoma in cancer. Principles and practice of oncology. In: De Vita VT Jr, Heilman S, Rosenberg SA (eds) Lippincott, Philadelphia, p 1137Google Scholar
  2. 2.
    Köhler G, Milstein C (1975) Continuous culture of fused cells secreting antibody of predefined specificity. Nature 256:495–497PubMedCrossRefGoogle Scholar
  3. 3.
    Brown JP, Nishiyama K, Hellström I, Hellström KE (1981) Structural characterization of human melanoma associated antigen p97 using monoclonal antibodies. J Immunol 127:539–546PubMedGoogle Scholar
  4. 4.
    Woodberry RJ, Brown JP, Yeh M-Y, Hellström I, Hellström KE (1981) Identification of a cell surface protein, p97 in human melanomas and certain other neoplasms. Proc Natl Acad Sci USA 77:2183–2186CrossRefGoogle Scholar
  5. 5.
    Hellstrom I, Garrigues HJ, Cabasco L et al. (1983) Studies of a high molecular weight human melanoma-associated antigen. J Immunol 130:1467–1472PubMedGoogle Scholar
  6. 6.
    Larson SM, Brown JP, Wright PW et al. (1983) Imaging of melanoma with I-131-labeled monoclonal antibodies. J Nucl Med 24:132–139Google Scholar
  7. 7.
    Larson SM, Carrasquillo JA, Krohn KA et al. (1983) Diagnostic imaging of malignant melanoma with radiolabeled anti-tumor antibodies. JAMA 249:811–812PubMedCrossRefGoogle Scholar
  8. 8.
    Larson SM, Carrasquillo JA, Krohn KA (1982) Radiotherapy with “anti-p97” iodinated monoclonal antibodies in melanoma. In: Raynaud C (ed) Proceedings of the 3rd World Congress of Nuclear Medicine and Biology, August-September, 1982, Paris, vol IV. Pergamon, New York, pp 3666–3669Google Scholar
  9. 9.
    Larson SM, Carrasquillo JA, Krohn KA et al. (1983) Localization of 131I-labeled p97-spe- cifíc Fab fragments in human melanoma as a basis for radiotheapy. J Clin Immunol 72:1201–1221Google Scholar
  10. 10.
    Ferens JM, Krohn KA, Beaumier PL et al. (1984) High-level iodination of monoclonal antibody fragments for radiotherapy. J Nucl Med 25:367–370PubMedGoogle Scholar
  11. 11.
    Hellström I, Hellström KE, Brown JP et al. (1983) Monoclonal antibodies to human melanoma antigens — possible clinical applications. Clin Immunol Newsletter 8:71–74CrossRefGoogle Scholar
  12. 12.
    Larson SM, Carrasquillo JA (1983) Nuclear oncology: Current perspectives. In: Freeman LM, Weissman HS (eds) Nuclear Medicine Annual. Raven, New York, pp 167–198Google Scholar
  13. 13.
    Larson SM, Carrasquillo JA (1984) Nuclear oncology 1984. Semin Nucl Med XTV:268–276CrossRefGoogle Scholar
  14. 14.
    Carrasquillo JA, Larson SM, Hellström KE et al. (1983) Radioimmuno-detection of tumor melanoma with monoclonal antibodies and Fab fragments. In: Burchiel SW, Roades BA (eds) Radioimmunoimaging and Radioimmunotherapy. Elsevier, New York, pp 357–368Google Scholar
  15. 15.
    Larson SM, Carrasquillo JA (1984) Role of labelled antibodies in tumor detection and possible treatment Curr Concepts Diagn Nucl Med 1:13–16Google Scholar
  16. 16.
    Carrasquillo JA, Krohn KA, Beaumier PL et al. (1984) Diagnosis and treatment of solid tumors with radiolabelled antibodies and immune fragments. Cancer Treat Rep 68:1984Google Scholar
  17. 17.
    Larson SM, Carrasquillo JA, McGuffin RW et al. (1985) Preliminary clinical experience using an I-131 labeled murine Fab against a high molecular weight antigen of human melanoma. Radiology 155:487–492PubMedGoogle Scholar
  18. 18.
    Beaumier PL, Carrasquillo JA, Krohn KA et al. (1985) Localization of I-125 anti-p97 monoclonal Fab fragments in nude mice implanted with human melanoma xenografts. J Nucl Med 26:1172–1179PubMedGoogle Scholar
  19. 19.
    Halpern SE, Hagen PL, Carver PR, Cosial JA, Chen AWN, Franke JM, Bartholomew RM, Davis GS, Adams TH (1983) Stability characterization and kinetics of indium-111 labeled monoclonal antitumor antibodies in normal animals and nude mice. Human tumor models. Cancer Res 43:5347–5355PubMedGoogle Scholar
  20. 20.
    Neumann RD, Kirkwood JM, Zoghbi SS et al. (1985) Ga-67 vs In-lll-DTPA-anti-p97 monoclonal antibody (MoAb) for scintigraphic detection of metastatic melanoma. J Nucl Med 26:15Google Scholar
  21. 21.
    Carrasquillo JA, Abrams PG, Schroff RW, Keenan AM et al. (1985) Improved Imaging of metastatic melanoma with high dose 9.2.27 In-111 monoclonal antibody. J Nucl Med 26:67Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • S. M. Larson
    • 1
  • J. A. Carrasquillo
  • J. C. Reynolds
  • I. Hellström
  • K.-E. Hellström
  1. 1.Chief Department of Nuclear Medicine, CCNational Institutes of HealthBethesdaUSA

Personalised recommendations